Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects*; D000941:Antigens / Q000008:administration & dosage; D004137:Dinitrochlorobenzene / Q000276:immunology; D004926:Escherichia coli / Q000276:immunology; D005260:Female; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects*; D012673:Semustine / Q000009:adverse effects*; D013745:Tetanus Toxoid / Q000276:immunology; D013997:Time Factors
D000941:Antigens; D004137:Dinitrochlorobenzene; D009607:Nitrosourea Compounds; D013745:Tetanus Toxoid; D012673:Semustine; D006433:Hemocyanins